These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2574447)

  • 1. Selective dopamine D1 and D2 receptor antagonists.
    Hyttel J; Arnt J; van den Berghe M
    Psychopharmacol Ser; 1989; 7():109-22. PubMed ID: 2574447
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic neuroleptic treatment and dopamine receptor regulation.
    Creese I; Snyder SH
    Adv Biochem Psychopharmacol; 1980; 24():89-94. PubMed ID: 6105809
    [No Abstract]   [Full Text] [Related]  

  • 4. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole-induced tardive dyskinesia: the role of tamoxifen.
    Evcimen YA; Evcimen H; Holland J
    Am J Psychiatry; 2007 Sep; 164(9):1436-7. PubMed ID: 17728431
    [No Abstract]   [Full Text] [Related]  

  • 6. Is there a presynaptic tardive dyskinesia?
    Bowers MB; Glazer WM
    J Clin Psychopharmacol; 1987 Feb; 7(1):57-9. PubMed ID: 2880877
    [No Abstract]   [Full Text] [Related]  

  • 7. Sulpiride in tardive dyskinesia.
    Gerlach J; Casey DE
    Acta Psychiatr Scand Suppl; 1984; 311():93-102. PubMed ID: 6142590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment.
    Peacock L; Lublin H; Gerlach J
    Eur J Pharmacol; 1990 Sep; 186(1):49-59. PubMed ID: 1980891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current status of our knowledge of the neurotropic side effects of neuroleptic drugs].
    Sabbatini F; Pinessi L; Gentile S; De Mattei M; Portaleone P
    Minerva Psichiatr; 1983; 24(4):145-53. PubMed ID: 6145083
    [No Abstract]   [Full Text] [Related]  

  • 10. Sulpiride-induced tardive dystonia.
    Miller LG; Jankovic J
    Mov Disord; 1990; 5(1):83-4. PubMed ID: 1967484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Are the antipsychotic and side-effects of neuroleptics imperfectly known?].
    Schulz P
    Biomed Pharmacother; 1987; 41(1):31-3. PubMed ID: 2886159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity.
    McQuade RD; Duffy RA; Coffin VL; Barnett A
    Eur J Pharmacol; 1992 Apr; 215(1):29-34. PubMed ID: 1355442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyskinesia induced by long-term treatment with antipsychotic drugs: involvement of pre- and postsynaptic dopaminergic mechanisms.
    Engel J; Liljequist S; Goldstein M
    Adv Biochem Psychopharmacol; 1980; 23():387-95. PubMed ID: 6104913
    [No Abstract]   [Full Text] [Related]  

  • 14. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
    Millan MJ; Iob L; Péglion JL; Dekeyne A
    Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The receptor-binding profile of neuroleptic agents].
    Eneman M
    TVZ; 1990 Feb; (3):89-93. PubMed ID: 1969274
    [No Abstract]   [Full Text] [Related]  

  • 16. Dopamine D-1 and D-2 receptors in relation to reward and performance: a case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs.
    Miller R; Wickens JR; Beninger RJ
    Prog Neurobiol; 1990; 34(2):143-83. PubMed ID: 1969668
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuroleptic plasma levels and tardive dyskinesia.
    Giller E
    Schizophr Bull; 1980; 6(3):391-2. PubMed ID: 6105706
    [No Abstract]   [Full Text] [Related]  

  • 18. Dopamine receptor function and spontaneous orofacial dyskinesia in rats during 6-month neuroleptic treatments.
    Waddington JL; Cross AJ; Gamble SJ; Bourne RC
    Adv Biochem Psychopharmacol; 1983; 37():299-308. PubMed ID: 6138952
    [No Abstract]   [Full Text] [Related]  

  • 19. Tardive dyskinesia and dopamine receptors.
    Hyttel J; Nielsen IM
    Lancet; 1979 Dec; 2(8155):1300. PubMed ID: 93212
    [No Abstract]   [Full Text] [Related]  

  • 20. Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients.
    Chouinard G; Annable L; Ross-Chouinard A
    Psychopharmacol Bull; 1986; 22(3):891-6. PubMed ID: 2879310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.